Acceleron Pharma Profit Margin

As of the most recent data (September 2021), XLRN shows a profit margin of -226.01%. That compares with -124.73% in the prior-year period — down 81.2% year over year. That is below the Healthcare sector average of 10.58%. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, XLRN's profit margin is now -226.01% (was -124.73%) — a 81.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Acceleron Pharma is outperforming or lagging.

The Healthcare sector average profit margin is about 10.58%. Acceleron Pharma is at -226.01%, which is lower that average. That is roughly 2236.1% below the sector mean. Use the comparison chart on this page to see how XLRN stacks up against individual peers as well.

That compares with -124.73% in the prior-year period — down 81.2% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Acceleron Pharma with peers to see if the move is company-specific or sector-wide.

Besides this profit margin page, Stockcircle has Acceleron Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -226.01%) with ownership activity and broader fundamentals.